Inclusion Criteria:  Adults between 18-99, English or Spanish speaking ≥8 weeks of laryngeal symptoms (dysphonia, throat clearing, cough, globus, and/or sore throat) Current use of double dose PPI* (equivalent to: omeprazole 40mg daily, lansoprazole 30mg daily, esomeprazole 40mg daily, dexlansoprazole 60mg daily, rabeprazole 20mg daily, or pantoprazole 80mg daily) Laryngoscopic exam within 12 months prior to screening with reflux finding score >7 Fasting salivary pepsin concentration of ≥25 ng/mL at screening or within 4 months of enrollment  Exclusion Criteria:  Prior use of Reflux Band (UES Compression Device) Sino-pulmonary conditions (such as asthma, COPD, post-nasal drip, heavy voice use) as primary etiology of laryngeal symptoms as deemed by treating gastroenterologist and / or laryngologist Laryngeal mass or lesion on laryngoscopy Pregnant or breastfeeding Unable to consent in English or Spanish Imprisoned PPI intolerance Patients with a prior foregut surgery Patients with a known achalasia diagnosis Inability to fast for 4 hours Active tobacco use Supplemental oxygen use Contraindication to UES Compression Device manufacturer guidelines: Patients with implants or implant parts that reside in the area where Reflux Band is applied: implanted pacemarker, implanted cardioverter defibrillator (ICD), vagus nerve stimulator (VNS), or other such devices implanted in the neck Patients diagnosed with glaucoma. Patients who had a malignancy of the neck, including neck surgery. Patients that may have an altered mental status including due to the use of sedative drugs or narcotics. Patients with carotid artery disease, uncontrolled thyroid disease, a history of cerebrovascular disease, or connective tissue disorder of Marfan's Syndrome or Ehlers-Danlos Syndrome Patients who use nocturnal NIV machines such as CPAP or BiPAP.